Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial
Official title:
A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas
Verified date | June 2013 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may help irinotecan kill more cancer cells by making cancer cells more sensitive to the drug. Giving oxaliplatin together with irinotecan may kill more cancer cells.
Status | Completed |
Enrollment | 24 |
Est. completion date | |
Est. primary completion date | September 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 1 Year to 21 Years |
Eligibility |
Inclusion Criteria: - Histologically confirmed refractory malignant solid tumor or lymphoma - Intrinsic brain stem tumors and optic pathway tumors do not require histologic verification - No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists - Measurable or evaluable disease - Evaluable disease is defined as a tumor that cannot be measured using a ruler or calipers, but can be assessed to determine disease progression or complete response, such as any of the following: - Positive lesions on metaiodobenzylguanidine (MIBG) or bone scan - Metastatic bone marrow disease - Elevated tumor markers - Presence of a malignant pleural effusion - No leukemia - Performance status - Karnofsky 50-100% (for patients > 10 years of age) - Performance status - Lansky 50-100% (for patients = 10 years of age) - Not specified - Absolute neutrophil count = 1,000/mm^3 - Platelet count = 100,000/mm^3 (transfusion independent) - Hemoglobin = 8.0 g/dL (transfusion allowed) - Bilirubin = 1.5 times upper limit of normal (ULN) - ALT = 5 times ULN - Albumin = 2 g/dL - Creatinine clearance or radioisotope glomerular filtration rate = 70 mL/min - Creatinine based on age as follows: - No greater than 0.8 mg/dL (for patients age 5 and under) - No greater than 1.0 mg/dL (for patients age 6 to 10) - No greater than 1.2 mg/dL (for patients age 11 to 15) - No greater than 1.5 mg/dL (for patients age 16 and over) - No arrhythmia on EKG - No evidence of dyspnea at rest - No exercise intolerance - Pulse oximetry > 94% on room air and no evidence of pulmonary fibrosis by chest radiograph* or CT scan - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception - Weight = 10 kg - Neurologic deficits relatively stable for = 1 week before study entry (patients with CNS tumors only) - No electrolyte (e.g., sodium, potassium, bicarbonate, calcium, magnesium, and phosphate) abnormality = grade 2 (electrolyte supplementation allowed) - No uncontrolled infection - No history of life-threatening allergy to camptothecin derivatives or platinum agents - No sensory or motor peripheral neuropathy = grade 2 - No elevation of amylase or lipase = grade 2 - Able to tolerate enteral medications (e.g., cefixime, cefpodoxime, or loperamide) - Recovered from all prior immunotherapy - At least 7 days since prior hematopoietic growth factors - At least 7 days since prior antineoplastic biologic therapy - Prior stem cell transplantation or rescue without total-body irradiation (TBI) allowed provided = 3 months have elapsed and there is no evidence of active graft-versus-host disease - No concurrent immunotherapy - No concurrent biologic therapy - More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered - No prior oxaliplatin - No other concurrent chemotherapy - Concurrent steroids allowed provided dose has been stable for = 7 days before study entry - See Biologic therapy - Recovered from all prior radiotherapy - At least 2 weeks since prior local palliative small port radiotherapy - At least 6 months since prior TBI - At least 6 months since prior craniospinal, whole spinal, or whole lung/abdominal radiotherapy - At least 6 months since prior radiotherapy to = 50 % of the pelvis - At least 6 weeks since other prior substantial radiotherapy to the bone marrow - No concurrent radiotherapy - No other concurrent investigational drugs - No other concurrent anticancer therapy - No concurrent cephalosporin antibiotics - No concurrent use of any of the following: - Phenytoin - Carbamazepine - Oxcarbazepine - Barbiturates - Rifampin - Phenobarbital - Azole antifungal agents - Aprepitant - Hypericum perforatum (St. John's wort) |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | COG Phase I Consortium | Arcadia | California |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MTD of oxaliplatin, defined as the maximum dose at which fewer than one-third of patients experience DLT | Graded using the NCI CTCAE version 3.0. | 21 days | Yes |
Secondary | Overall response assessed using RECIST criteria | Up to 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01164163 -
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
|
Phase 1 | |
Terminated |
NCT00949117 -
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
|
Phase 2 | |
Completed |
NCT00985868 -
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00253474 -
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
|
Phase 1 | |
Completed |
NCT00281944 -
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00084695 -
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
|
Phase 2 | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT00003070 -
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
|
Phase 3 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003754 -
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
|
Phase 2 | |
Completed |
NCT00016861 -
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
|
Phase 1 | |
Completed |
NCT00004005 -
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT00898794 -
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
|
N/A | |
Terminated |
NCT00429702 -
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
|
Phase 2 | |
Completed |
NCT00459238 -
Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants
|
N/A | |
Completed |
NCT00387920 -
Sunitinib in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00138216 -
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00070473 -
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors
|
Phase 1 |